Literature DB >> 22669454

Characteristic immunophenotype of solid subtype component in lung adenocarcinoma.

Teruhisa Takuwa1, Genichiro Ishii, Kanji Nagai, Junji Yoshida, Mitsuyo Nishimura, Tomoyuki Hishida, Shinya Neri, Seiki Hasegawa, Atsushi Ochiai.   

Abstract

BACKGROUND: Lung adenocarcinomas represent a morphologically heterogeneous tumor composed of an admixture of different histologic subtypes (lepidic, papillary, acinar, and solid subtype). The presence of a solid subtype component is reported to be associated with a poorer prognosis. The aim of this study was to evaluate the characteristic immunophenotype of the solid subtype component compared with the immunophenotypes of other components.
METHODS: We analyzed the clinicopathological characteristics of stage I adenocarcinoma patients with predominant solid subtype disease. Furthermore, we immunostained adenocarcinomas with predominant lepidic, papillary, acinar, and solid subtype components (n = 23 each) for 10 molecular markers of tumor invasiveness and scored the results.
RESULTS: Patients showing predominance of the solid subtype component (solid subtype adenocarcinoma) had a poorer prognosis than those showing predominance of the lepidic, papillary, or acinar component. Lymphovascular invasion was more often detected in solid subtype tumors than in others. The solid subtype component showed a significantly stronger staining intensity of laminin-5 expression than the lepidic, papillary, and acinar components (P < 0.001, P < 0.001, and P = 0.016, respectively). The fibronectin and vimentin expression levels were also significantly higher in the solid subtype component than in other components. This immunostaining character was validated by using mixed-subtype adenocarcinomas containing all four components in the same tumor.
CONCLUSIONS: This study concluded that the solid subtype component in lung adenocarcinomas exhibit the invasive immunophenotype, including increased laminin-5 expression, compared with the other components, which may be associated with a poorer prognosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669454     DOI: 10.1245/s10434-012-2428-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  The difference in Ezrin-pAkt signaling axis between lepidic and papillary predominant invasive adenocarcinomas of the lung.

Authors:  Kazunori Hata; Junji Yoshida; Hibiki Udagawa; Hiroko Hashimoto; Satoshi Fujii; Tomoyuki Hishida; Takeshi Kuwata; Keiju Aokage; Motohiro Kojima; Atsushi Ochiai; Kenji Suzuki; Masahiro Tsuboi; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-08       Impact factor: 4.553

2.  Clinicopathological significance of caveolin-1 expression by cancer-associated fibroblasts in lung adenocarcinoma.

Authors:  Kei Shimizu; Keisuke Kirita; Keiju Aokage; Motohiro Kojima; Tomoyuki Hishida; Takeshi Kuwata; Satoshi Fujii; Atsushi Ochiai; Kazuhito Funai; Junji Yoshida; Masahiro Tsuboi; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-22       Impact factor: 4.553

3.  Metastatic spread of solid subtype lung adenocarcinoma to the small intestine with anemia and melena: A case report.

Authors:  Xiaofang Ying; Mingwei Wang; Vivek Verma; Manxiang Wang; Shengwei Ye; Jianping Bi; Xiaoyi Zhou; Guang Han; Weining Zhen
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

4.  Alteration of the E-Cadherin/β-Catenin Complex Is an Independent Poor Prognostic Factor in Lung Adenocarcinoma.

Authors:  Hyojin Kim; Seol Bong Yoo; Pingli Sun; Yan Jin; Sanghoon Jheon; Choon Taek Lee; Jin-Haeng Chung
Journal:  Korean J Pathol       Date:  2013-02-25

5.  Genetic analyses of differences between solid and nonsolid predominant lung adenocarcinomas.

Authors:  Jizhuang Luo; Ke Ma; Yu Shi; Zongwei Chen; Mengnan Zhao; Yiwei Huang; Shuai Wang; Junjie Xi; Cheng Zhan; Songtao Xu; Qun Wang
Journal:  Thorac Cancer       Date:  2018-10-01       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.